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ABSTRACT 
Mortalities from cancer in the world are projected to continue rising, with an estimated 9 million and 11.4 million people dying from cancer in 
2015 and 2030, respectively. Rates are rising as more people live to an old age and as mass lifestyle changes occur in the developing world. 
With present treating regimen for cancer, dose-limited toxicity is a big reason that reduces the efficacy of cancer treatments. In search for more 
effective cancer treatments, nanosized drug delivery systems, those are capable of delivering their drug payload selectively to cancer cells such 
as nanoparticles, solid lipid nanoparticles, liposomes are among the most promising approaches. Core shell nanoparticles are one of the 
investigated moieties in recent years that are seeking much attention nowadays for biomedical applications including the field of oncology.The 
present work aims at developing a core shell nanoparticle comprising Poly (D, L –lactide –co –glycolide) (PLGA) core and polyethyleneimine 
(PEI) shell loaded with anticancer bioactive docetaxel (DTX) for passive targeting of the tumor tissue. It is expected that incorporation of PEI 
will improve the uptake and subsequent release of the drug in the cytosol due to endosomal escape phenomenon.  
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1. INTRODUCTION 
Cancer, a dreadful disease, is one of the chief killers today 
worldwide. Medical treatment of cancer still has many 
challenges yet to meet and the medicines used in the treatment 
of cancer have their own boundaries. The main remedial 
therapies for cancer, e.g. surgery, radiation and chemotherapy, 
are generally successful in the early stages of cancer. Once the 
tissue has progressed to higher stages, these therapies are less 
successful. Chemotherapy among all the stated therapies is most 
effective but only for defined period of time. The currently used 
chemotherapeutic agents are the drugs with the narrowest 
therapeutic indices in all medicines. Thus, the dose of anticancer 
agents is restricted by their non-selective toxic effects on healthy 
cells 1.  
Selective and targeted delivery of cytotoxic drugs into 
malignant tumors may overcome these limitations. Even 
highly toxic agents could be rendered safer and more 
effective, if it were possible to direct them only into the 
tumor because high drug concentrations within the tumor 
could be obtained while sparing the normal tissues. These 
harmful side effects can be reduced by developing a drug 
delivery vehicle that is specific to tumor cells and this may be 
achieved by employing a strategy which makes advantage of 
abnormal tumor vasculature. Poorly formed leaky 
vasculature of tumors contributes for the well-known 
enhanced permeation and retention (EPR) effect that allows 
selective accumulation of polymer-drug conjugates/ 
complexes ranging in size between 10 to 500 nm within 
tumors when compared to that of free drugs  2, 3.  
The polymeric molecules are retained following the 
accumulation due to their larger size and abnormal 
lymphatic supply to the vasculature whereas free drug 
molecules are easily eliminated from the cells 4. Controlled 
drug delivery strategies have made a dramatic impact in 
medicine. Progress in novel targeting strategy is paving way 
for more safe and effective management of various diseases 
like cancer, tuberculosis, malaria, arthritis, cardiovascular 
diseases etc. The ability to transport a large quantity of drug 
molecules into cytosolic compartments of cancer cells has 
powerful implications in modern molecular therapeutics 
because the sites of action of the drugs are often cytosolic 
organelles. Furthermore, direct cytosolic delivery might offer 
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a means to evade efflux transporters, such as P 
glycoproteins. Fast cytoplasmic drug delivery can overcome 
cancer cells drug resistance and thus have an enhanced 
therapeutic efficacy. Core-shell architecture represents an 
effective way to attain multiple functionalities on a 
nanoscopic length scale. Indeed, a core (template) 
generally carrying a chemotherapeutic agent can be surroun
ded by a shell with different composition and configuration 
that provides a functional and interacting interface with 
biological environment. They found application in Drug 
delivery, both in vitro and in vivo diagnostics, nutraceuticals 
and production of improved biocompatible materials. The 
present work aims at developing a core shell nanoparticle 
comprising Poly (D, L-lactide-co-glycolide) (PLGA) core and 
Polyethyleneimine (PEI) shell loaded with anticancer 
bioactive docetaxel (DTX) for passive targeting of the tumor 
tissue. It is expected that incorporation of PEI will improve 
the uptake and subsequent release of the drug in the cytosol 
due to endosomal escape phenomenon.  
2. MATERIALS  
Poly (D, L-lactide-co-glycolide) (PLGA) and DOCETAXEL was 
obtained as a gift sample from M/s. Sun Pharma Advanced 
Research Center (SPARC), Vadodra, Gujarat, India. Branched 
PEI (Polyethyleneimine) (MW: 25 kDa), Pluronic F-68, was 
purchased from Sigma Aldrich, India. All other reagents and 
solvents used were of analytical grade. Unless stated 
otherwise double deionized water was used throughout the 
study.  
3. METHODS 
3.1 Preparation of PLGA nanoparticles 
PLGA nanoparticles were synthesized by emulsion solvent 
evaporation method with slight modifications 5. Figure 1 
represents the pictorial presentation of preparation of 
nanoparticles. In order to obtain stable formulation, different 
process and formulation parameters were optimized as 
follow.
 
 
Figure 1 Pictorial presentation of preparation of nanoparticles 
 
3.2 Optimization of Nanoparticle Formulation 
It was done by taking into consideration of critical 
parameters which influence the property and stability of 
nanoparticles. One parameter was optimized at a time 
keeping all other parameters constant.  These variables are 
shown below. 
3.2.1 Optimization of Formulation Variables 
3.2.1.1 Optimisation of polymer concentration 
For optimization of Polymer concentration (PLGA), the 
nanoparticle formulations were prepared with varying 
concentrations of PLGA keeping other parameters constant. 
Optimization was done on the basis of average particle size 
and drug entrapment efficiency of nanoparticle, which were 
determined using Nanosereis ZS90 zetasizer (Malvern, UK) 
(Figure 2).  
 
Figure 2 Optimisation of polymer concentration 
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3.2.1.2 Optimisation of Surfactant Concentration 
For optimization of surfactant concentration, different 
nanoparticles formulations were prepared with different 
concentrations (0.5%, 1%, 2%, 3%) of surfactant (Pluronic F-
68) keeping the other parameters constant. Optimization 
was done on the basis of average particle size of nanoparticle 
and % Drug Entrapment (Figure 3). 
 
Figure 3 Optimisation of Surfactant Concentration 
3.2.1.3 Optimization of Sonication Time 
For the optimization of sonication time, the formulation was 
sonicated (Probe Sonicator) for 60, 120,180, 240 sec using 
probe sonicator and average particle size and % drug 
entrapment efficiency were recorded (Figure 4). 
 
Figure 4 Optimization of Sonication Time 
3.2.1.4 Optimization of Aqueous Phase Volume: Aqueous 
phase volume also affects the particle size. The volume was 
varied from 10 to 30 mL and average particle size, % drug 
entrapment efficiency and PDI were recorded (Figure 5). 
 
Figure 5: Optimization of Aqueous Phase Volume 
3.3 Preparation of PLGA-PEI Nanoparticles  
To fabricate PEI-coated PLGA NPs, 5 mg of PEI that was disso
lved in 5 mL distilled water (adjusted pH 8) was added to 5 
mL of an aqueous solution containing 10 mg of PLGA NPs an
d mixed by stirring for 1 hour. The emulsion was washed thr
ee times with 10 mL of distilled water by centrifugation (6,50
0×g, 10 minutes) at 4°C, freeze-dried, and stored at 20°C 6. 
3.4 Characterization of Formulation 
The optimized nanoparticles were characterized on various 
attributes like particle size, surface charge, PDI, SEM and in-
vitro evaluation. 
3.4.1 Particle Size Determination and Surface Charge 
Measurement 
The average particle size and size distribution of the PLGA 
NPs and PEI-PLGA NPs were determined by Nanoseries 
Zetasizer ZS90 (Malvern) and are represented in figure 6 (A) 
& (B) and 7 (A) & (B) respectively. The samples of 
formulation were diluted to 1:9 v/v with deionized water. 
The particles size and size distribution were represented by 
average (diameter) of the Gaussion distribution function in 
the logarithmic axis mode. The zeta potential (є) of the 
nanoparticles formulation was calculated according to 
Helmholtz-Smoluchowsky from their electrophoretic 
mobility. For measurement of zeta potential, Zetasizer 
(NanoPlus) was used. 
 
 
 
Figure 6(A) Particle size of PLGA-NPs and (B) Zeta Potential of PLGA-NPs 
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Figure 7(A) Particle size of PLGA-PEI NPs and (B) Zeta Potential of PLGA- PEI NPs 
 
3.4.2 Surface and Shape Morphology  
Morphology of drug loaded nanoparticle formulations (D-PLGA NPs and D-PEI-PLGA NPs) was determined by Scanning 
Electron Microscopy (SEM) at Dr. H.S. Gour Central University, Sagar and at SIL, Dr. H.S. Gour Central University, Sagar (Figure 8 
(A) & (B), respectively).  
 
 
Figure 8 SEM images: (A) PLGA-NPs and (B) PLGA-PEI NPs 
 
3.4.3 Entrapment Efficiency 
Entrapment efficiency of the drug loaded nanoparticles was determined by using Sephadex G–50 column 7 (Table 1). 
% Entrapment efficiency =
100
 drug  totalofAmount 
 drug free ofAmount  - drug  totalofAmount 
  
3.4.4 Physicochemical characteristics of different drug loaded NPs: A summary 
Table 1 represents a brief summary of physicochemical characteristics of different drug loaded NPs. 
 
Table 1: A brief summary of physicochemical characteristics of different drug loaded NPs 
Formulation code Size (nm) PDI Zeta potential (mV) %EE 
PLGA 168±3.12 0.180±0.011 -11.7±1.6 69.34±1.53 
PLGA-PEI 201±3.81 0.448±0.013 32.3±1.9 72.4±2.26 
Values represent mean ± SD (n = 3)  
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3.5 Cumulative Percent Drug Release 
The in vitro drug release of entrapped drug from different 
formulation was determined using dialysis tube method at 
physiological pH and acidic pH as the atmosphere of tumor 
tissue is slightly acidic and hence the change in release 
pattern was studied (Figure 9(A) and (B), respectively) 8.  
 
 
Figure 9 Cumulative percent drug release at (A) pH 7.4 (B) 
pH 5.0 
 
3.6 MTT cytotoxicity assay 
3.6.1 Cell culture  
MCF 7cell line was selected for tumor studies. The cells were 
cultured in RPMI supplemented with 10% Fetal Bovine 
Serum (FBS), 1% streptomycin/penicillin, 2mM of glutamine, 
maintained at 37±1°C and 5% CO2 under humidified 
conditions 9. 
3.6.2 Assessment of cellular toxicity 
Inhibition of cell proliferation was studied by tetrazolium 
salt (3-[4,5-dimethylthiazol-2-yl]- 2-5-diphenyl tetrazolium 
bromide. Briefly, cells were seeded in a 96 well flat bottom 
plates and allowed to grow for 24 hr. Then, the cells were 
incubated with increasing concentration of DTX solution, D-
PLGA NPs and D-PLGA-PEI NPs for 24 hr. After 24 hr, the 
supernatant was removed; MTT and culture medium (100 µL 
each) were added to each well and incubated for 4 hr at 
37◦ C and 5% CO2 atmosphere. The unreduced MTT and 
medium were then discarded. Each well was washed with 
200 µL of PBS, and 200 µL of DMSO was added to dissolve 
the MTT formazan crystals. Plates were shaken for 20 min 
and absorbance was read at 560 nm using a microplate 
reader (Molecular Devices Corporation, USA). The IC50 values 
(i.e., concentration resulting in 50% growth inhibition) of 
docetaxel were graphically calculated from concentration-
viability curves, considering the optical density of the control 
well as 100% viable (Figure 10). 
 
Figure 10 Cell viability (in percent) after treatment of MCF-7 
cells with different formulations. 
                                
4. RESULTS AND DISCUSSION  
PLGA nanoparticles were fabricated by a modified emulsion/ 
solvent evaporation method (Figure 1) using after 
optimizing the different formulation variables using one 
factor at a time approach wherein the factors were optimized 
varying one parameter at a time keeping other constant as 
per the literature available. Polymer concentration, 
surfactant concentration, sonication time and aqueous 
volume ratio were the factor optimized (Figure 2, 3, 4 and 5, 
respectively). Particle size and % drug entrapped were the 
parameters observed for optimizing the plain and drug 
loaded formulation. The optimized methodology used for 
nanoparticle fabrication includes the use of 2% w/v PLGA in 
ethyl acetate as organic Phase and 1 % w/v Pluronic F-68 in 
water as stabilizer. Drug loading was done by dissolving 2% 
w/w drug in organic phase. Particle size, size distribution 
and surface charge of nanoparticles were determined using 
Zetasizer (Malvern ZS 90, UK). The average size of the PLGA 
nanoparticles (PLGA-NPs) and PLGA-PEI nanoparticles 
(PLGA-PEI-NPs) was observed to be 168±2.7 nm and 
201±3.81 nm respectively [Figure 6 (A) & 7(A)]. Zeta 
potential is one of the most important indices to evaluate 
nanoparticulate suspension stability. The value of the zeta 
potential was found to be -11.7 mV for PLGA-NPs due to the 
presence of terminal carboxylic groups in the polymer. For 
PLGA-PEI-NPs it was found to be 32.3±1.9 mV [Figure 6(B) & 
7(B)] which is indicative of the presence of PEI imine group 
on the surface. SEM image of nanoparticles showed that 
particles were spherical in shape and do not show 
considerable variation in shape [Figure 8 (A) & (B)]. The 
results are in accordance with previous report 10-12. Drug 
loading was optimized on the basis of particle size and 
percentage entrapment efficiency so as to load the maximum 
possible amount of the drug in the system. Percent drug 
entrapment was calculated using Sephadex G-50 column. 
Formulation with highest percentage of loaded drug was 
selected for in vitro release behavior in media of various 
ionic strengths (pH7.4 and pH 5.0) [Figure 9(A) & 9(B)]). At 
acidic pH, the system showed comparatively faster release 
due to the protonation of the various groups present on the 
surface of carrier system. The formulations were also studied 
for MTT assay. In order to evaluate the cytotoxic potential of 
developed formulations for MCF-7 cell at various time 
periods are presented in figure 10. The antiproliferative 
activity of different DTX-NPs formulation on MCF-7 cell line 
was observed at 24 hr in concentration range of 0.1µg/ml 
to10 µg/ml. The results showed that the free DTX have 
slightly higher IC50 value than DTX PLGA nanoparticles after 
24 hr with values of 6.1±0.12, 4.2±0.22 and 2.1±0.24 µg/ml 
after 24 hr for DTX, D-PLGA-NPs and D-PLGA-PEI NPs 
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respectively. PEI coated nanoparticles have lower IC50 value 
and there was significant difference in the IC50 values of PEI 
coated nanoparticles as compared to other formulations, 
suggesting that PEI coated nanoparticles showed highest 
cytotoxicity against these cells at all concentrations as 
compared to PLGA NPs and free drug.  
CONCLUSION  
In our current study, we used modified core shell 
nanoparticle comprising the PLGA core and 
polyethylenimine (PEI) in order to improve the therapeutic 
index of docetaxel against MCF-7 cancer cells. The 
nanoparticles were prepared by emulsion/solvent 
evaporation technique followed by their characterization 
based upon size and surface charge. A rise in the surface zeta 
potential of the nanoparticles confirms the electrostatic 
binding of PEI with the surface of PLGA nanoparticles. 
Scanning electron microscopy (SEM) was employed to 
observe the shape, dispersion, and morphology of the 
nanoparticles. We found that PEI coated PLGA NPs was 
nanometric in size, uniform in shape and showed good 
entrapment efficiency of 72.4%. The developed formulation 
showed sustained drug release.  PEI- coated PLGA 
nanoparticles demonstrated a more potent cytotoxic eﬀect 
on MCF-7 cancer cells over longer time duration. The results 
shown in this study are promising and set a platform for 
further examining the suitability of this PEI-enhanced 
delivery system for cancer therapy. 
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